Alan Russell is the Co-Founder and Chief Scientific Officer of Edgewise Therapeutics, based in Boulder CO, dedicated to the discovery and development of novel medicines to treat Duchenne muscular dystrophy and other severe, inherited muscle diseases. Previously, Dr. Russell served at GlaxoSmithKline as VP and Head of the Muscle Metabolism Discovery Performance Unit, leading a broad discovery and development effort focused on patients for whom muscle function is compromised. Prior to this, he worked at Cytokinetics Inc. and is the co-inventor of Tirasemtiv and Reldesemtiv, direct muscle sensitizers in clinical trials for Amyotrophic Lateral Sclerosis (ALS).
Dr. Russell received a B.Pharm. in Pharmacy and Pharmacology and Ph.D. in Cell Biology and Gene Therapy from the University of Bath in the UK and Postdoctoral training at the Stanford University School of Medicine. He has been active in the discovery and development of medicines to improve skeletal muscle health for the last 20 years.